Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E. Walsh, William C. Gruber, Kristin Tompkins et al.|New England Journal of Medicine|2020Cited by 2.7k
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesUğur Şahin, Özlem Türeci, Alexander Muik et al.|Nature|2020Cited by 2.1k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adultsMark J. Mulligan, Kathrin U. Jansen, Kirsten E. Lyke et al.|Nature|2020Cited by 1.6k
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy StudyEdward E. Walsh, William C. Gruber, Robert W. Frenck et al.|medRxiv|2020Cited by 155
A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primatesAnnette B. Vogel, Ricardo Carrion, Isis Kanevsky et al.|bioRxiv (Cold Spring Harbor Laboratory)|2020Cited by 139